Briefs: Caplin Point Laboratories, Hikal and Cipla

Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru

Aurbindo Pharma posts Q3 FY25 profit at Rs. 846 Cr

During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.

Akums reports Q3 FY25 adjusted PAT at Rs. 66.3 Cr

Branded formulation business continues to perform well across domestic and export markets

Gandhar Oil Refinery (India) Q3 FY25 consolidated revenues reaches Rs. 1,005.3 Cr

Consolidated manufacturing volumes for Q3 FY25 remained stable at 132,187 KL, while for 9M FY25 it stood at 372,505 KL

India reaffirms commitment to global pharmaceutical standardization and regulatory convergence: Anupriya Patel

International Meeting of World Pharmacopoeias serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization

Pfizer reports 2024 revenues 7% higher at $63.6 billion

Fourth-quarter 2024 revenues totaled $17.8 billion, an increase of $3.2 billion

Hikal appoints Dr. Raghavendar Morthala as Head – CDMO R&T Pharma & Animal Health BU

Carbogen Amcis appoints Stephan Fritschi as CEO

Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.

Akums combines two potent diabetes medicines for enhanced treatment efficacy

Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management

Zydus Wellness records consolidated net sales growth of 12.7% in Q3 FY25

EBITDA rose to Rs. 14.8 crore, marking a 16.5% y-o-y increase, while net profit surged to Rs. 6.4 crore